Low-Dose Tofacitinib for Treating Patients with Severe Alopecia Areata: An Efficient and Cost-Saving Regimen

    December 2019 in “ European Journal of Dermatology ”
    Yang‐Yi Chen, Sheng-Yiao Lin, Yin-Chun Chen, Chao‐Chun Yang, Cheng‐Che E. Lan
    From the encyclopedia
    Tofacitinib →

    a JAK inhibitor for alopecia areata and other autoimmune conditions

    Alopecia Areata →

    autoimmune disorder causing patchy hair loss

    Studysummary This study identified new and recurrent missense mutations in the PHGDH and PSAT1 genes, implicating them in the pathogenesis of Neu-Laxova syndrome in Chinese patients.
    Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
    The study explored the use of low-dose tofacitinib as a treatment for severe alopecia areata (AA), highlighting its potential as an efficient and cost-saving regimen. Tofacitinib, a selective Janus kinase (JAK) 1 and 3 inhibitor, had been previously used at higher dosages of 10 to 20 mg daily for treating severe AA. However, the study aimed to evaluate the therapeutic response of a lower-dosage regimen, which had not been thoroughly assessed before. The lower dosage was suggested to offer clinical advantages, such as reduced medical costs and fewer potential adverse effects, making it a promising alternative for patients with severe AA.
    Discuss this study in the Community →

    Research cited in this study

    7 / 7 results